Company Reports

Recent Updates

All Reports

Company Report

Moderna's mRNA technology gained rapid validation as sales of its COVID vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat, largely because of uncertainties tied to an evolving virus and a changing competitive and regulatory landscape for innovative vaccines. However, Moderna is making progress applying its mRNA technology to oncology, which could support competitive advantages down the road.
Company Report

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due to uncertainties tied to an evolving virus and the changing competitive landscape and regulatory landscape for innovative vaccines.
Company Report

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due to uncertainties tied to an evolving virus and the changing competitive landscape and regulatory landscape for innovative vaccines.
Company Report

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due to uncertainties tied to an evolving virus and the changing competitive landscape and regulatory landscape for innovative vaccines.
Stock Analyst Note

Moderna reported $389 million in revenue in the first quarter, but research and development spending and a $900 million legal settlement drove a $1.3 billion net loss. Moderna maintained guidance for up to 10% revenue growth in 2026. Shares fell 3% intraday on May 1.
Company Report

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due to uncertainties tied to an evolving virus and the changing competitive landscape and regulatory landscape for innovative vaccines.
Stock Analyst Note

Moderna reported third-quarter $1 billion in revenue (45% decline) and a $200 million net loss. Management updated full-year guidance, including narrowed revenue guidance and lower cost of sales and operating expenses, resulting in a higher expected $6.5 billion-$7.0 billion year-end cash balance.

Sponsor Center